TLDR:
- Boston Oncology Arabia, a bio-generic drugs manufacturing company in Saudi Arabia, received a $35M investment from TVM Capital.
- The investment will be used to enhance the company’s move into full formulation and fill and finish manufacturing at its local production facility.
Boston Oncology Arabia, a Riyadh, Saudi Arabia-based bio-generic drugs manufacturing company, has received a $35M investment from TVM Capital. The company, led by CEO and Founder Abdullah Baaj, plans to use the funds to further enhance its move into full formulation and fill and finish manufacturing at its local production facility in Sudair Industrial City. This investment will also allow TVM Capital Healthcare to provide strategic support and leverage its global network to expand the company’s access to international suppliers.
Boston Oncology Arabia is focused on providing vital medicines for critical conditions through the local development and manufacturing of internationally licensed therapeutics. By supplying care medicines through flexible, local manufacturing facilities and leveraging international relationships for licensing from Western and Eastern markets, the company is contributing to Saudi Arabia’s Vision 2030 goals.
Abdullah Baaj, CEO of Boston Oncology Arabia, expressed his gratitude for the investment, stating that the company’s localization model is designed to create value in complex and competitive markets. With the support of TVM Capital Healthcare, Boston Oncology Arabia aims to bring cutting-edge, specialized manufacturing to the GCC and MENA region, impacting the lives of millions of patients.
